Aug. 24 at 11:32 AM
$MIST With a drug intended for two indications—SPVT and, above all, AFib RvR—which has over 10 million patients in the United States alone, we assume a 35% penetration, then China and Europe will follow. Reminding everyone that Cardamyst works, with a 17-25 minute response time, and it allows you to avoid hospitalization, saving insurance companies around
$8-9,000. It changes the lives of those in need, especially those whose lives are changed. I think that approval for AFib RvR will arrive at the end of 2028/first 6 months of 2029. All this if it isn't purchased before then
